Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: ValuEngine, Inc.
$25.00
Provider: Pechala's Reports
$15.00
Provider: Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Amarin Corporation PLC Announces Approval Of Supplemental New Drug Application For Chemport As Additional Vascepa Active Pharmaceutical Ingredient Supplier


Thursday, 18 Apr 2013 06:00am EDT 

Amarin Corporation PLC announced that the approval of the Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) to add Chemport, Inc. as an additional Vascepa (icosapent ethyl) active pharmaceutical ingredient (API) supplier. 

Company Quote

1.94
0.04 +2.11%
3:38pm EDT